Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

JPMorgan analysts revised their outlook on Novo Nordisk (NYSE:NVO) stock, reducing the price target to DKK1,000 from DKK1,050. Despite the adjustment, they maintained an Overweight rating on the ...

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S . Shareholders who purchased shares of NVO ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.